Chronic pain — defined as pain persisting beyond 3 months beyond the expected period of healing, or associated with chronic conditions — affects an estimated 50 million American adults (20.9%) and represents the most common reason for primary care visits and specialist referrals in the United States. The opioid crisis — which caused 80,000 overdose deaths in 2023 alone, driven predominantly by illicit fentanyl — has transformed prescribing culture, restricting opioid access in ways that sometimes leave undertreated pain patients with poor alternatives. The clinical challenge: identifying and implementing the full range of evidence-based non-opioid and multimodal treatments that can achieve meaningful pain reduction and functional improvement for the vast majority of patients.
Central Sensitization: Rethinking Chronic Pain Biology
The dominant neurobiological framework for understanding chronic pain has shifted from a tissue-damage model to one centered on central sensitization — amplification of pain signals by the central nervous system independent of ongoing peripheral nociception. In central sensitization, normal stimuli are perceived as painful (allodynia), noxious stimuli are perceived as more intense than expected (hyperalgesia), and pain spreads beyond the original injury site. This framework explains conditions including fibromyalgia, widespread chronic low back pain, irritable bowel syndrome, and chronic headache as fundamentally disorders of pain modulation rather than tissue injury — and has profound therapeutic implications, pointing toward treatments that target central rather than peripheral pain mechanisms.
Pharmacological Non-Opioid Options
The evidence-based non-opioid pharmacological armamentarium includes: SNRIs (duloxetine, venlafaxine) — FDA-approved for fibromyalgia, diabetic peripheral neuropathy, and chronic musculoskeletal pain, with NNTs of 5–7; Gabapentinoids (gabapentin, pregabalin) — effective for neuropathic pain (diabetic neuropathy, postherpetic neuralgia, NNT 6–8) but with abuse potential and cognitive side effects limiting broad application; Tricyclic antidepressants — low-dose amitriptyline and nortriptyline remain highly effective for multiple chronic pain conditions (NNT 3–4 for neuropathic pain) at doses below antidepressant threshold; Topical agents — lidocaine patches (Lidoderm), diclofenac gel, and capsaicin 8% patch (Qutenza) provide meaningful localized neuropathic pain relief with minimal systemic effects; Low-dose naltrexone (LDN, 1.5–4.5 mg/day) — growing evidence for fibromyalgia, Crohn's-associated pain, and CRPS through glial modulation.
Interventional Pain Procedures
For appropriately selected patients, interventional procedures provide targeted pain relief: epidural steroid injections for radicular pain (NNT 7.5 for >50% relief); medial branch nerve blocks and radiofrequency ablation for facet-mediated low back pain (2-year pain relief rates of 60–70%); spinal cord stimulation for failed back surgery syndrome and complex regional pain syndrome (CRPS) — the SENZA-RCT demonstrated 50% spinal cord stimulation superiority over conventional medical management for persistent spinal pain after surgery at 24 months; intrathecal drug delivery systems for cancer pain and refractory neuropathic pain. The COAPT trial demonstrated dorsal root ganglion (DRG) stimulation superiority over spinal cord stimulation for CRPS, representing a significant advancement for one of pain medicine's most challenging conditions.
Pain Psychology and Acceptance-Based Therapies
Cognitive behavioral therapy for chronic pain (CBT-CP), Acceptance and Commitment Therapy (ACT), and mindfulness-based stress reduction (MBSR) have among the strongest evidence for meaningful, sustained improvement in chronic pain outcomes — improving pain-related disability, catastrophizing, depression, and quality of life in well-designed RCTs. The SCOPE of Pain curriculum, used in over 2,000 US clinical practices, standardizes evidence-based opioid prescribing practices including PMP review, risk stratification, and multimodal co-prescribing. Healthcare facilities managing chronic pain patients need comprehensive clinical supplies including orthopedic and rehabilitation equipment and wound and skin care products for patients with neuropathic conditions.
